Substantial Mortality Benefits Expected From Optimal Medication Use for HFrEF

WEDNESDAY, Oct. 16, 2024-- For individuals with heart failure with reduced ejection fraction (HFrEF), substantial mortality benefits would result from optimal use of guideline-directed medical therapy (GDMT), according to a study published online...